| Title | Anlotinib plus Sintilimab as First-line Treatment for Patients with Advanced Colorectal Cancer (APICAL-CRC): an Open-Label, Single-arm, Phase II trial |
|---|---|
| Description | This study aimed to evaluate the combination of sintilimab and anlotinib in treatment-naive mCRC patients. This was an investigator-initiated, open-label, single-arm, phase II trial conducted in treatment-naive mCRC patients. Eligible patients received sintilimab 200 mg intravenously on day 1, plus anlotinib 12 mg orally daily from days 1 to 14, with a treatment cycle of every 3 weeks. The primary endpoint was the objective response rate (ORR), assessed by investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. |
| Organism | Homo sapiens |
| Data Type | Non-coding RNA Profiling |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA042908 |
| Release Date | 2025-07-11 |
| Submitter | Dongyu Liu (dongyu.liu@3dmedcare.com) |
| Organization | 3D Medicines Inc. |
| Submission Date | 2025-07-10 |
The data cannot be downloaded as it has not yet been registered in the Human Genetic Resource Management Platform of MOST.
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download |
|---|---|---|---|---|---|---|
| OMIX010910-01 | clean_read_count.txt | 1 | Non-coding RNA Profiling | 280.9 KB | txt | Unavailable |
| Paper Title | Journal Name | Publish Time | Accession | Citing Type |
|---|---|---|---|---|
| Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial | Signal Transduction and Targeted Therapy | 2025-09 | OMIX010910 | Deposit |